Jim Simons Adagio Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	N/A	382,818 New	382,818 $1.27 Million
Q4 2023 Feb 13, 2024	SELL	N/A	-21,585 Reduced 44.25%	27,200 $107,000
Q3 2023 Nov 14, 2023	BUY	N/A	24,585 Added 101.59%	48,785 $83,000
Q2 2023 Aug 11, 2023	BUY	N/A	3,700 Added 18.05%	24,200 $25,000
Q1 2023 May 12, 2023	BUY	N/A	4,700 Added 29.75%	20,500 $25,000
Q4 2022 Feb 13, 2023	BUY	$3.08 - $4.05 $48,664 - $63,990	15,800 New	15,800 $24,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.